Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Diagnosis, Pathology & Staging

At a Glance

Diffuse gastric cancer grows deep in the stomach wall, meaning standard biopsies often miss it. Accurate diagnosis requires specialized tests like Endoscopic Ultrasound (EUS) and a staging laparoscopy to check for microscopic spread, ensuring your medical team chooses the right treatment plan.

The diagnosis and staging of diffuse gastric adenocarcinoma require a different approach than other stomach cancers. Because this cancer spreads “horizontally” through the stomach wall’s deeper layers rather than forming a single lump, it can be invisible to standard tests [1][2]. Your medical team must use specialized tools to “see” where the cancer is hiding and determine the best treatment path.

Why Standard Biopsies Can Miss It

During a standard endoscopy, a doctor looks at the inner lining of the stomach (the mucosa). However, diffuse gastric cancer often lives in the submucosa—the layer underneath the lining [2].

  • The “Stretch Sign”: Doctors look for subtle clues, like a stomach wall that doesn’t expand properly when air is pumped in (reduced distensibility) [3][4].
  • The Depth Problem: A standard biopsy tool only snips a tiny piece of the surface. If the cancer is growing deeper down, the biopsy may come back “negative” even if the cancer is there [2].

Specialized Diagnostic Tools

To overcome these challenges, two specific procedures are often used:

  1. Endoscopic Ultrasound (EUS): This uses a special endoscope with an ultrasound probe on the tip. It allows doctors to see through the stomach wall layer by layer [5].
  2. Fine-Needle Biopsy (FNB): If a suspicious area is found deep in the wall, the doctor uses EUS to guide a thin needle into that specific layer to pull out a tissue sample [6][7]. This is much more accurate for diffuse-type cancers and potential linitis plastica than surface biopsies [8][6].

The Critical Role of Staging Laparoscopy

For diffuse gastric cancer, a CT scan is not enough. This subtype has a high risk of spreading to the peritoneum (the lining of the abdominal cavity) in tiny droplets that are too small for a CT or PET scan to see [9][10].

Staging Laparoscopy is a minor surgical procedure where a surgeon inserts a tiny camera through a small incision in your abdomen [10]. This is considered an absolute requirement for diffuse-type cancer because:

  • It allows the surgeon to see the abdominal lining directly [11].
  • The surgeon can perform “peritoneal washings,” where they rinse the cavity with fluid and check it under a microscope for hidden cancer cells [10].
  • In about 25% of cases, this procedure finds spread that was missed on scans, which completely changes the treatment plan to avoid unnecessary major surgery [10].

Understanding Your Pathology Report

Your pathology report is the “blueprint” for your care. For diffuse gastric cancer, look for these key elements:

Element What It Means for You
Lauren Classification Must specify “Diffuse-type.” This warns the team that the cancer may be less responsive to certain standard chemotherapies [12][13].
Signet Ring Cells Confirms the diffuse subtype; these cells are aggressive and spread easily [14].
TNM Staging T (Tumor depth), N (Lymph nodes), and M (Metastasis/Spread). For diffuse cancer, the T and N are the strongest predictors of the outcome [15].
Margins If you have had surgery, this tells you if the edges of the removed tissue were clear. Diffuse cancer often requires wider margins (often 5-8 cm) because cells can hide in seemingly healthy tissue [16].
Biomarkers Testing for HER2, PD-L1, and Claudin 18.2 helps determine if targeted therapies or immunotherapy could work for you [17][18].

Molecular and Genetic Testing

Because some diffuse gastric cancers are linked to the CDH1 gene mutation (Hereditary Diffuse Gastric Cancer), your doctor may recommend genetic testing, especially if you have a family history of stomach or lobular breast cancer [19][20]. Finding this mutation can change the surgical approach and may mean family members need to be tested [21].

Common questions in this guide

Why didn't my regular endoscopy biopsy show diffuse gastric cancer?
Diffuse gastric cancer often grows beneath the surface lining of the stomach in the submucosa. Because standard endoscopies only biopsy a tiny piece of the surface lining, they can easily miss cancer cells hiding in the deeper layers.
What is the purpose of a staging laparoscopy for stomach cancer?
A staging laparoscopy allows a surgeon to look directly at the lining of your abdomen and perform fluid washings. This procedure is crucial because diffuse gastric cancer can spread in microscopic droplets that are invisible on regular CT or PET scans.
What does it mean if my pathology report shows signet ring cells?
The presence of signet ring cells on a biopsy confirms the diffuse subtype of gastric cancer. These specific cancer cells are known to be aggressive and can easily spread horizontally through the deeper stomach tissues.
Should I get genetic testing if I have diffuse gastric cancer?
Genetic testing is often recommended for diffuse gastric cancer, especially if you have a family history of stomach or lobular breast cancer. Testing looks for a mutation in the CDH1 gene, which can change your surgical plan and alert family members of their risk.
Why do surgeons need wider margins when removing diffuse gastric cancer?
Because diffuse gastric cancer cells spread outward and hide in seemingly healthy tissue, surgeons must remove a larger area of surrounding tissue. Taking wider margins ensures that no microscopic cancer cells are left behind after surgery.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Why is staging laparoscopy recommended for me even if my CT scan looked clear?
  2. 2.Will you be performing peritoneal washings during the laparoscopy to look for microscopic cancer cells?
  3. 3.My initial biopsy was shallow; should we perform an Endoscopic Ultrasound (EUS) with a fine-needle biopsy to get a deeper sample?
  4. 4.What was my PD-L1 (CPS) score and HER2 status? Are there other biomarkers like Claudin 18.2 that we should test for?
  5. 5.Does my pathology report indicate that the tumor is 'diffuse-type' according to the Lauren classification?
  6. 6.If surgery is an option, how large of a 'margin' (the safe zone of healthy tissue) do you plan to take to ensure no hidden cells are left behind?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Superficial Flat-Type Early-Stage Gastric Signet Ring Cell Carcinoma in the Atrophic Background Mucosa: Two Case Reports.

    Wang W, Yang Y, Xu Q, et al.

    Journal of gastrointestinal cancer 2023; (54(2)):677-681 doi:10.1007/s12029-022-00812-4.

    PMID: 35304679
  2. 2

    Endoscopic ultrasound-guided fine-needle aspiration biopsy for diagnosis of gastric linitis plastica with negative malignant endoscopy biopsies.

    Ye Y, Tan S

    Oncology letters 2018; (16(4)):4915-4920 doi:10.3892/ol.2018.9258.

    PMID: 30250557
  3. 3

    Endoscopic features of early-stage signet-ring-cell carcinoma of the stomach.

    Phalanusitthepha C, Grimes KL, Ikeda H, et al.

    World journal of gastrointestinal endoscopy 2015; (7(7)):741-6 doi:10.4253/wjge.v7.i7.741.

    PMID: 26140102
  4. 4

    Author's reply to the letter to the editor on "A case of gastric signet-ring cell carcinoma with a long-term retrospective follow-up of 17 years".

    Muraishi J, Miyaoka M, Imamura K, et al.

    Clinical journal of gastroenterology 2022; (15(1)):270 doi:10.1007/s12328-021-01546-9.

    PMID: 34724193
  5. 5

    The role of EUS in missed and known linitis plastica.

    Khara HS, Stewart DM, Confer BD, et al.

    Endoscopic ultrasound 2020; (9(3)):202-204 doi:10.4103/eus.eus_20_18.

    PMID: 32584317
  6. 6

    Gastric linitis plastica due to signet-ring cell carcinoma with Krukenberg tumors diagnosed by endoscopic ultrasound-guided fine-needle aspiration.

    Okamoto T, Suzuki H, Fukuda K

    Clinical journal of gastroenterology 2021; (14(4)):994-1003 doi:10.1007/s12328-021-01387-6.

    PMID: 33740238
  7. 7

    Endoscopic Ultrasound-guided Tissue Acquisition of Pancreatic Malignancy: A Retrospective Study at a Tertiary Center.

    Constantinescu A, Pavel C, Plotogea OM, et al.

    Romanian journal of internal medicine = Revue roumaine de medecine interne 2025; (63(2)):175-184 doi:10.2478/rjim-2025-0008.

    PMID: 40262059
  8. 8

    A case report of gastric linitis plastica diagnosed by endoscopic ultrasound-guided fine needle aspiration.

    Muraoka S, Tsuchida K, Iwasaki M, et al.

    Medicine 2017; (96(50)):e8937 doi:10.1097/MD.0000000000008937.

    PMID: 29390283
  9. 9

    Staging laparoscopy in patients with advanced gastric cancer: A single center cohort study.

    Borgstein ABJ, Keywani K, Eshuis WJ, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2022; (48(2)):362-369 doi:10.1016/j.ejso.2021.08.003.

    PMID: 34384656
  10. 10

    The yield of diagnostic laparoscopy with peritoneal lavage in gastric adenocarcinoma: A retrospective cohort study.

    van Hootegem SJM, Chmelo J, van der Sluis PC, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2024; (50(4)):108233 doi:10.1016/j.ejso.2024.108233.

    PMID: 38428107
  11. 11

    STAGING LAPAROSCOPY IS STILL A VALUABLE TOOL FOR OPTIMAL GASTRIC CANCER MANAGEMENT.

    Sakamoto E, Ramos MFKP, Pereira MA, et al.

    Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery 2023; (35()):e1700 doi:10.1590/0102-672020220002e1700.

    PMID: 36629683
  12. 12

    Clinicopathological Variation of Lauren Classification in Gastric Cancer.

    Chen YC, Fang WL, Wang RF, et al.

    Pathology oncology research : POR 2016; (22(1)):197-202 doi:10.1007/s12253-015-9996-6.

    PMID: 26502923
  13. 13

    Differential prognostic implications of gastric adenocarcinoma based on Lauren's classification: a Surveillance, Epidemiology, and End Results (SEER)-based cohort study.

    Tang D, Ni M, Zhu H, et al.

    Annals of translational medicine 2021; (9(8)):646 doi:10.21037/atm-20-7953.

    PMID: 33987344
  14. 14

    Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study.

    Li Y, Ma FH, Xue LY, Tian YT

    World journal of gastroenterology 2020; (26(8)):818-827 doi:10.3748/wjg.v26.i8.818.

    PMID: 32148379
  15. 15

    Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy.

    Song Y, Hirata Y, Ajani JA, et al.

    Annals of surgical oncology 2024; (31(10)):6918-6930 doi:10.1245/s10434-024-15893-7.

    PMID: 39048909
  16. 16

    A standardized pathology report for gastric cancer: 2nd edition.

    Park YS, Kook MC, Kim BH, et al.

    Journal of pathology and translational medicine 2023; (57(1)):1-27 doi:10.4132/jptm.2022.12.23.

    PMID: 36647283
  17. 17

    Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer.

    Zeng Y, Jin RU

    Seminars in cancer biology 2022; (86(Pt 3)):566-582 doi:10.1016/j.semcancer.2021.12.004.

    PMID: 34933124
  18. 18

    Mismatch repair deficiency and its relationship with histopathological features in gastric cancer patients.

    Nguyen THC, Nguyen TBS, Nguyen TP, et al.

    Nagoya journal of medical science 2025; (87(1)):93-104 doi:10.18999/nagjms.87.1.93.

    PMID: 40255992
  19. 19

    Inherited CDH1 pathogenic variant: is there a place for surveillance of esophageal gastric inlet patch?

    Leclercq P, Jadot V, Bours V, et al.

    Therapeutic advances in gastroenterology 2020; (13()):1756284820916399 doi:10.1177/1756284820916399.

    PMID: 32523621
  20. 20

    Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer.

    Huynh JM, Laukaitis CM

    Molecular genetics & genomic medicine 2016; (4(2)):232-6 doi:10.1002/mgg3.197.

    PMID: 27064202
  21. 21

    Diagnosis and Management of Hereditary Gastric Cancer.

    Monahan KJ, Hopkins L

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2016; (205()):45-60 doi:10.1007/978-3-319-29998-3_4.

    PMID: 27075348

This page explains diagnosis, pathology, and staging terminology for diffuse gastric adenocarcinoma for educational purposes only. Always consult your oncology team for the interpretation of your specific test results, biopsies, and scans.

Get notified when new evidence is published on diffuse gastric adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.